SCHEDULE: Perceptive Advisors Discloses 5.4% Stake in Sutro Biopharma

Perceptive Advisors LLC and Joseph Edelman have reported a 5.4% beneficial ownership stake in Sutro Biopharma, Inc. via a Schedule 13G filing.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have collectively reported beneficial ownership of 898,025 shares of Sutro Biopharma, Inc. common stock.
• This holding represents 5.4% of the company's total outstanding common stock, based on 16,567,238 shares outstanding as of March 16, 2026.
• The reporting persons share voting and dispositive power over the entire 898,025 share position.
• The filing confirms the shares were acquired for investment purposes without the intent to change or influence control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects institutional interest in the company's equity without indicating any immediate corporate restructuring or activist pressure.

Positives

• Institutional investor confidence indicated by a significant 5.4% equity position.
• The investment is classified as passive, suggesting support for current management and strategic direction.

Negatives

• None identified in this regulatory disclosure.

Risks

• Market volatility associated with biotechnology sector investments.
• Reliance on the accuracy of the issuer's reported outstanding share count for ownership percentage calculations.

Future Outlook

The filing does not provide forward-looking guidance, as it is a standard disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Perceptive Advisors is a well-known healthcare-focused investment firm; their accumulation of a 5% stake in a biotech firm is often viewed by the market as a positive signal regarding the company's clinical pipeline or valuation.

Comparison to Industry Standards

• The filing follows standard SEC requirements for institutional investors crossing the 5% ownership threshold.
• The passive investment stance is consistent with typical 13G filings by specialized life sciences investment funds.

Stakeholder Impact

• Shareholders may view the entry of a major life sciences investor as a validation of the company's long-term prospects.

Next Steps

• The reporting persons will be required to file amendments if there are material changes to their ownership percentage.

Key Dates

Keywords

Sutro Biopharma, Perceptive Advisors, Schedule 13G, Biotechnology, Institutional Ownership, Equity Stake